By Maggie Fick and Mariam Sunny (Reuters) -Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish drugmaker’s new CEO to spur growth. Mike Doustdar, who took the helm at the […]
Business
Novo to buy Akero for up to $5.2 billion in new CEO’s revival push
Audio By Carbonatix
By Maggie Fick and Mariam Sunny
(Reuters) -Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish drugmaker’s new CEO to spur growth.
Mike Doustdar, who took the helm at the Wegovy maker in July, has signaled a focus on new, highly effective obesity and diabetes drugs that can also treat related cardiometabolic conditions such as MASH, rather than expanding into other areas.
Akero’s drug candidate, efruxifermin, is currently in late-stage trials for treating metabolic dysfunction-associated steatohepatitis (MASH).
“We view this deal, coupled with recent internal restructuring at Novo, positively as Doustdar works to bring the ship back on course,” said BMO Capital analyst Evan Seigerman.
Under Doustdar, tasked with stemming market share losses to U.S. rival Eli Lilly, the company last month said it would cut 9,000 jobs.
HIGH GROWTH POTENTIAL
Efruxifermin has shown potential in reversing liver scarring in MASH patients in earlier studies.
Doustdar called it “an important building block” for future growth, especially as Novo prepares for the loss of exclusivity on semaglutide, the active ingredient in blockbuster drug Wegovy, starting next year in regions like India and China.
Lukas Leu, a portfolio manager at Novo Nordisk shareholder ATG Healthcare, said it was encouraging to see Novo seal a major deal and expand in a high-growth area, where rivals such as Roche and GSK have also made recent moves.
In August, Wegovy became the first GLP-1 drug to receive accelerated approval for MASH in the U.S., where the disease affects around 5% of adults.
Novo has discontinued its MASH candidate, zalfermin, which belonged to the same class of treatments as efruxifermin.
DEALS GETTING BIGGER
Akero marks a significant increase in deal size for Novo, as its recent biotech acquisitions in metabolic diseases typically ranged between $1 billion and $2 billion.
“They need to start acquiring assets and expanding their pipeline,” Leu said, adding that he remains cautious given the stock is “still in the doghouse”.
Novo shares have risen 11% since Doustdar’s appointment, but remain down nearly 40% for the year, reflecting investor concerns over Wegovy’s U.S. prescription trends.
The Akero deal includes an upfront cash payment of $54 per share held, totaling about $4.7 billion, a 16.2% premium over Akero’s last closing price.
An additional $6 per share will be paid if efruxifermin secures full U.S. approval by June 2031.
Akero’s shares rose over 16% in afternoon trading, while Novo shares slipped 1%.
Novo plans to finance the acquisition through debt and expects to close the deal by the end of the year.
(Reporting by Anna Ringstrom in Stockholm, Mariam Sunny in Bengaluru and Maggie Fick in London; Editing by Essi Lehto, Leroy Leo and Sriraj Kalluvila)